Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of Kylo-0603 Capsule in Study Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT07878091 is registered in ClinicalTrials.gov with Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT07878091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07878091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of Kylo-0603 Capsule in Study Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Lead sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 15, 2026
Completion date
August 15, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-associated steatoic liver disease